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Brain tumor-initiating cells (BTICs) have been identified as key con-
tributors to therapy resistance, recurrence, and progression of
diffuse gliomas, particularly glioblastoma (GBM). BTICs are elusive
therapeutic targets that reside across the blood–brain barrier, under-
scoring the urgent need to develop novel therapeutic strategies.
Additionally, intratumoral heterogeneity and adaptations to thera-
peutic pressure by BTICs impede the discovery of effective anti-BTIC
therapies and limit the efficacy of individual gene targeting. Recent
discoveries in the genetic and epigenetic determinants of BTIC tu-
morigenesis offer novel opportunities for RNAi-mediated targeting
of BTICs. Here we show that BTIC growth arrest in vitro and in vivo is
accomplished via concurrent siRNA knockdown of four transcription
factors (SOX2, OLIG2, SALL2, and POU3F2) that drive the proneural
BTIC phenotype delivered by multiplexed siRNA encapsulation in the
lipopolymeric nanoparticle 7C1. Importantly, we demonstrate that
7C1 nano-encapsulation of multiplexed RNAi is a viable BTIC-
targeting strategy when delivered directly in vivo in an established
mouse brain tumor. Therapeutic potential was most evident via a
convection-enhanced delivery method, which shows significant ex-
tension of median survival in two patient-derived BTIC xenograft
mouse models of GBM. Our study suggests that there is potential
advantage in multiplexed targeting strategies for BTICs and estab-
lishes a flexible nonviral gene therapy platform with the capacity to
channel multiplexed RNAi schemes to address the challenges posed
by tumor heterogeneity.
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Glioblastoma (GBM) is one of the most challenging tumors totreat (1, 2). Despite decades of research and maximal clinical
combination therapy encompassing surgical resection, chemother-
apy, and radiation, the median life expectancy of patients has not
been extended beyond 2 y after diagnosis (2). Increasing evidence
suggests that the genetic, epigenetic, and signaling heterogeneity of
GBM underlies the ineffectiveness of currently available therapeu-
tics (1, 2). Additionally, therapeutic schemes devised to challenge
brain tumor cells are frequently thwarted by insufficient delivery
caused by pharmacokinetics, the blood–brain barrier (BBB), and an
altered tumor microenvironment in which tumor-derived signaling
recruits immunomodulatory cells and induces extracellular matrix
remodeling to build safe harbors of tumorigenic niches (3–5). These
obstacles call for tailored therapeutic strategies to counter tumor
heterogeneity and overcome roadblocks in delivery. RNAi targeting
drivers of tumorigenesis shows strong potential to supplement
the development of traditional small-molecule pharmaceutics (6).
However, delivery remains a key obstacle for efficient RNAi against
tumor drivers (5, 7, 8). RNA-sequencing analysis of patient tissue
combined with histology and in situ hybridization (Ivy Glioblastoma
Atlas Project; SI Appendix, Fig. S1) show that brain tumor-initiating
cells (BTICs) are found predominantly in the bulk of cellular tu-
mors, although their presence in vascular structures and perivascular
niches has also been highlighted in recent research (9–13). This
distribution pattern suggests that direct delivery to BTICs in the
tumor bulk is likely to be more advantageous than systemic delivery
approaches, which rely on BBB penetration to maximize the ther-
apeutic benefits of RNAi targeting BTICs.
A class of lipopolymeric nanoparticles (LPNPs) has been
formulated to maximize systemic delivery to vasculature-rich
organs for antitumor RNAi therapies, and the combination of
ionizable, low-molecular-weight lipopolymers custom synthe-
sized to optimize cell entry facilitates tumor cell targeting when
delivered directly (14–22). The polymers were synthesized by
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conjugating epoxide-terminated lipids to low-molecular-weight poly-
amines with an epoxide ring-opening reaction (23). The resul-
tant nano constructs then were evaluated for their ability to complex
with siRNA and knock down gene expression in vitro. The most
effective candidates were selected after in vivo assessment. One
compound, named “7C1,” was identified from a library of more than
500 candidate delivery materials as the most effective in silencing
target genes in vasculature, with a higher performance per dose ratio
than previously reported siRNA nano delivery vehicles (15, 23). The
capacity to multitarget and the ease of synthesis make 7C1 an at-
tractive therapeutic vehicle for antitumor RNAi. However, the ability
of 7C1 to penetrate the BBB has not been established.
A core set of four transcription factors (TFs), namely SOX2,
OLIG2, SALL2, and POU3F2, was recently proposed to drive
proneural BTICs (24). These TFs show high expression levels in
the bulk of patient tumor tissue (SI Appendix, Fig. S1). To evaluate
the feasibility of local delivery to BTICs directly in the core of
xenografts in mice, we opted to encapsulate combinations of
siRNAs in 7C1 LPNPs targeting the four TFs concurrently. Be-
cause other circuits are responsible for maintaining the stem cell-
like phenotypes in other GBM subgroups listed in The Cancer
Gene Atlas (TCGA), and because additional genetic/epigenetic
circuits are being identified (25–28), the current choice of RNAi
therapeutic targets is not expected to apply to all GBM subtypes.
The primary purpose of our work was to establish a proof-of-
principle approach and to demonstrate that tumorigenesis can
be antagonized using this vehicle and delivery strategy. Given that
TFs and other genetic and epigenetic targets were considered
“undruggable” by conventional pharmaceutical approaches, and
nanomedicine-mediated RNAi strategies have been formulated
primarily against membrane-bound or cytoplasmic effectors (29–
35), this direct approach in delivering RNAi therapeutics to target
tumorigenic gene circuits is a key step forward in diversifying our
strategies against one of the most challenging human cancers.
Results
TF Profiling and Selection of Tumor Cell Lines for Therapeutic Targeting.
To establish a suitable therapeutic target model using patient-derived
GBM BTICs, we cultured GBM cell lines in serum-free Neurobasal
medium supplemented for tumorsphere growth conditions (24, 25,
36). Cells then were collected for Western blotting and qRT-PCR
analysis of the expression levels of four core TFs (for primer se-
quences see SI Appendix, Table S1). Both assays indicate that BTICs
arising from different cell lines express dramatically variant levels of
TFs (Fig. 1 and SI Appendix, Fig. S2); however, MGG8 and
GBM43 display the most uniform levels of concurrent expression of
the four TFs in both mRNA and protein assays (Fig. 1 and SI Ap-
pendix, Figs. S3 and S4), and both cell types have been determined to
resemble most closely the proneural subclass of GBM, based on
TCGA criteria and genomic analysis (37, 38). Therefore, we chose
these two cell lines as TF-dependent BTIC models to examine the
feasibility and efficacy of TF RNAi therapy going forward.
Validation of Candidate siRNAs Targeting BTIC-Defining TFs. To se-
lect the optimal siRNA duplex for TF RNAi, we used sequence-
prediction services (Millipore Sigma) and generated three sets of
siRNA duplex designs, designated as siRNA1, siRNA2, and
siRNA3, for each TF (SI Appendix, Table S2) to test their efficacy in
knocking down TF expression. Dilution series were carried out to
determine the optimal in vitro TF mRNA knockdown, and com-
binations of all four finalists (combo siRNAs) were used to treat
cells before in vitro and in vivo functional assays to analyze the
tumorigenicity of the treated cells. qRT-PCR shows that the de-
livery of these siRNAs in combination resulted in at least 60%
mRNA knockdown by 24 h posttransfection, whereas the delivery of
two separate universal nontargeting negative controls did not (Fig.
2). The reduction in protein level became detectable on Western
blots and immunocytochemistry by 72 h posttransfection after
treatment with 50 nM of siRNA in complete medium (Fig. 2 and SI
Appendix, Fig. S3). The biological impact of these four TF knock-
downs has been studied through the shRNA strategy (24) in in vitro
and in vivo models, but the impact of transient siRNA knockdown,
the only clinically translatable approach, has yet to be investigated
in formed tumors in situ (39). BTICs treated with combo siRNAs
(50 nM for each TF siRNA) for 48 h demonstrated significantly
reduced tumor sphere formation and stem cell frequency for
MGG8 at cell densities greater than 25 cells per well in 96-well
plates (Fig. 3) and abolished single-cell clonal genesis, a hallmark of
tumorigenic behaviors (24). BTICs treated with combo siRNAs also
display changes in morphology and demonstrate adherent culture
with process development (Fig. 3A). Markers of early-stage differ-
entiation along the three neural lineages [e.g., GFAP for astroglia,
βIII tubulin (TUJ1) and neurofilament M (NFM) for early-stage
neuroprogenitors, and galactocerebroside (GALC) for early-stage
oligodendroglia] were observed via immunofluorescence (Fig. 3B).
However, cells plated at a higher density of cells in a single well
(e.g., more than three cells per well for MGG8, and various increases
in cells per well for GBM43) can still give rise to tumor spheres; the
dose impact of siRNA combinations needs to be explored in
the future (Fig. 3C). The in vitro assay was further supported by the
reduced tumorigenicity of MGG8 and GBM43 cells after combo
siRNA TF knockdown (50 nM of each TF siRNA for 48 h); when
these cells were implanted in athymic nude mice, survival was about
twice as long as when tumor cells treated with negative nontargeting
control siRNA were implanted (Fig. 3D). The eventual death of all
experimental mice indicates that single-dose transient knockdown of
master TFs is not a long-term solution in combating the malignant
growth of BTICs, and the impact on malignant tumor genome is
likely not sustainable. This finding led to the design of repeated or
sustained RNAi therapy in vivo to examine whether locally delivered
siRNA can maintain the suppression of expression.
Application of 7C1 LPNPs for BTICs. To examine whether the 7C1
nanoparticles (NPs) were suitable for BTIC targeting, we first
analyzed the in vitro uptake profiles of MGG8 BTICs using 7C1
LPNPs encapsulated with siRNAs tagged with the Alexa 647 flu-
orophore. Flow cytometry after an in vitro incubation time series
showed surprisingly faster uptake in BTICs than in mouse endo-
thelial cells at 1-h incubation, although by 12–24 h the percentage
of BTICs showing NP uptake plateaued at around 80% (Fig. 4A),
whereas both the mouse brain endothelial cell line bEnd3 and the
astrocyte line C8D1A saturated at nearly 100% (Fig. 4B). This
variance might be explained by the growth conditions of these cell
lines; BTICs were grown as a tumor sphere suspension, preventing
NP uptake in the core of spheres, which form quickly during the
Fig. 1. TF expression profiling of BTIC lines. Western blotting shows distinct
TF expression profiles of several patient-derived GBM BTIC lines. MGG8 and
GBM43 were selected for modeling of TF-dependent BTICs based on bal-
anced and relatively higher expression of all four TFs.
E6148 | www.pnas.org/cgi/doi/10.1073/pnas.1701911114 Yu et al.
incubation of the time series after the initial Accutase dissociation,
whereas bEnd3 and C8D1A were grown as adherent cells with flat
cell bodies that covered the entire surface area of the culture flasks
with maximal exposure to NPs. Serum-containing medium differ-
entiates BTICs (24) and changes the spherogenic growth conditions
of BTICs to adherent growth patterns. After 48 h of conditioning in
differentiation medium, MGG8 cells demonstrated a higher LPNP
uptake rate at 24 h of incubation, similar to that of the adherent
mouse brain cells (Fig. 4A). Confocal microscopy indicated that 7C1
NPs were readily endocytosed by BTICs, showing endosomal
presence at various stages (Fig. 4C), but more notable is the evi-
dence of endosomal escape at the early stages of LPNP uptake, in
that Alexa 647-tagged siRNA in LPNPs can be observed outside the
endosomes (Fig. 4C). Heterogeneous intracellular distribution of
the endocytosed LPNPs can be observed throughout different time
points after the initial treatment within the cell population, because
super-resolution nanoscale imaging via single-molecule localization
microscopy (SMLM) demonstrated a broad range of distances be-
tween antibody-labeled endosomes and the endocytosed LPNPs
(Fig. 4D, and see the enlarged view in SI Appendix, Fig. S5), sug-
gesting that perhaps more than one cell-entry mechanism was in-
volved. However, siRNA–LPNP accumulation in late endosomes
(RAB7+) may foreshadow a reduced efficiency in gene knockdown.
Future investigations to elucidate the exact cell-entry pathways are
needed. Interestingly, in vivo delivery of these LPNPs shows strong
affinity for BTICs (Fig. 4E), with minimal dispersal to nontumor
regions in vivo. Although the cell surface-targeting molecules of the
7C1 lipopolymeric formulation remain unknown, the in vitro and in
vivo selectivity for BTIC uptake establishes a solid rationale for
BTIC-targeted 7C1 delivery of therapeutic siRNAs.
Validation of LPNPs for Combination RNAi. Instead of using trans-
fection reagents, LPNPs serve as the packaging and delivery
vehicle by shielding the negative charge of the siRNA duplex
while offering the benefits of low toxicity and decreased liver
targeting and kidney clearance when given systemically in the
blood stream (23). To examine the feasibility of using LPNPs to
deliver RNAi to BTICs and potentially to a tumor-associated
microenvironment such as tumor-associated blood vessels, in
vitro knockdown of the four master TF mRNAs was performed
using 7C1 LPNPs formulated with a combination of siRNAs.
Assessment of both the mRNA and protein level confirmed
knockdown (Fig. 5), and tumorigenic spherogenesis was sup-
pressed (Fig. 5), albeit to a reduced extent when compared with
direct transfection at equivalent siRNA doses. This reduction
was likely caused by the endosomal retention of some of the NPs,
a well-known long-standing challenge for nanocarrier-mediated
siRNA knockdown. In addition, the impact of combo siRNA
packaged in LPNPs was different for the distinct GBM sub-
types, e.g., the spherogenic potential of MES83, a predominantly
mesenchymal BTIC subtype, showed little response to the combo
siRNA treatment (Fig. 5C). The predominant biological impact
Fig. 2. Validation of candidate siRNAs. Candidate siRNAs were selected for combination therapy against TF expression in BTIC models. (A) qRT-PCR dem-
onstration of effective mRNA knockdown with a combination of the four most effective siRNAs targeting the four TFs in both MGG8 and GBM43 cells (n = 4;
***P < 0.001, t test) (see SI Appendix, Table S2 for these siRNA duplex sequences). (B) Western blotting demonstration of the reduction in the level of TF
protein expression with multiplexed RNAi against all four TFs simultaneously. KD, knock down.
Fig. 3. Functional characterization of TF RNAi in vitro and in vivo. Validation of multiplexed RNAi on tumorigenicity. (A) Representative microscopy image of
tumor spheres formed from single BTICs (Left) and differentiated appearance of combo siRNA-treated tumor cells (Right). (B) Immunofluorescence probing of the
differentiation states of MGG8 BTICs receiving combo siRNA–LPNP treatment. After combo siRNA treatment for 48 h, BTICs gradually adopted an adherent
growth pattern and morphological indications of astroglial (glial fibrillary acid protein, GFAP+), neural (TUJ1+, or neural filament M/NFM+; yellow arrows), and
oligodendroglial differentiation (GALC+, green). (C) Extreme limiting dilution assay assessment of the limiting dilution spherogenic potential shows significantly
reduced tumor sphere formation at a high cell density per well in 96-well plates. Combo siRNA against TFs abolished single-cell spherogenesis for both the
GBM43 and MGG8 BTICs (n = 12; Pearson’s χ2 test). (D) Pretreatment of multiplex RNAi for both GBM43 and MGG8 BTICs significantly prolonged the survival of
animals injected with GBM43 or MGG8 cells (n = 5; log-rank test).
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of the LPNP-mediated combo siRNA treatment, based on the
Click-iT EdU assay and Ki67 immunostain flow cytometry as-
says, is the inhibition of cell proliferation (SI Appendix, Figs.
S6 and S7). However, different BTICs respond differently when
analyzed for cell death (SI Appendix, Fig. S8), with high-dose
treatments showing minor toxicity in normal human brain cells,
such as astrocytes (SI Appendix, Fig. S8A).
In Vivo Evidence of Tumor Growth Inhibition Mediated by the 7C1 NP–
siRNA Complex. To examine the potential of the7C1 siRNA–NP
complex for intratumoral delivery and tumor growth suppression,
GBM43 BTIC xenografts were established in mice based on bio-
luminescence imaging (BLI) signals of firefly luciferase (fLuc)-
positive GBM43 tumor mass formation after xenograft implanta-
tion. Mice then were given either nontargeting control siRNA–NP
treatments or combo siRNA-NP treatment for the TFs via intra-
tumoral injection. BLI signals indicate that the early-stage repeated
intratumoral injection of combo siRNA–NP complexes significantly
reduced tumor growth as compared with the injection of non-
targeting siRNA control NPs at the midpoint of the regimen (72 h
after second dosing) (Fig. 6). However, depending on the dosing
and frequency of combo siRNA–NP injections, the tumor-inhibiting
effects can be short lived (Fig. 6).
Contrasting in Vivo Delivery Strategies Resulted in Varying Therapeutic
Efficacy. The landmark demonstration of RNAi using double-
stranded siRNA in Caenorhabditis elegans (40) and subsequent in
vivo demonstration of siRNA therapeutic benefits (41) paved the
way for further advances in translational explorations of this
technology. Several obstacles with respect to tissue specificity and
sustainable potency must be overcome to achieve therapeutic
outcomes. Protection against naturally occurring nuclease cleav-
age, enhanced cellular uptake, and endosomal escape with charge
modification and the reduction of kidney clearance by increasing
Fig. 4. Characterization of siRNA–NP uptake profiles in vitro and in vivo. To characterize the siRNA–NP uptake dynamics in BTICs, in vitro LPNP loading was
performed on single-cell suspensions of MGG8 and serum-differentiated MGG8 cells. The bEnd3 mouse brain endothelial cell line and C8D1A mouse astrocytes
were used to compare the uptake profiles. (A) Cells were enzymatically digested into single-cell suspensions at various time points for flow cytometry analysis
after NP loading was done for different durations: 0, 1, 3, 12, and 24 h. Superimposed flow cytometry graphs collected after cells were loaded with siRNA (Alexa
647-tagged)–NP complexes show swifter uptake of siRNA–NPs in the BTICs than in the bEnd3 mouse brain endothelial cell line and the C8D1A mouse astrocyte
line. Serum in the culture medium changes MGG8 cells into adherent phenotypes and alters LPNP uptake dynamics. (B) MGG8 BTICs demonstrate a significantly
higher percentage of LPNP uptake by 1 h after seeding (n = 4, ***P < 0.001, t test). The NP+MGG8 cells plateaued at around 80% of the population by 12 h after
NP seeding, the plateauing is reversed by exposure to serum in the culture medium. Mouse bEnd3 and C8D1A cells became nearly saturated by 12 h of NP–siRNA
seeding. (C) Confocal microscopy of MGG8 cells shows nearly uniform rapid uptake of FAM-tagged siRNA–NP complexes (green dots) in the cytosol, with some
colocalization with the early endosomal marker EEA1 (red signals; yellow indicates colocalization) (Top Row) or RAB5 (red signal) (Middle Row). By 12 h, some of
the siRNA–NP complexes were consolidated to RAB7+ late endosomes (yellow signals) (Bottom Row). (D) SMLM super-resolution images of the cells shown in C are
analyzed for the relative distances between endosomes (green dots) and the endocytosed Alexa 647-tagged siRNA–LPNPs (red dots). An enlarged view is shown in
SI Appendix, Fig. S5. The diverse distribution patterns of distances between LPNPs and endosomes at different time points postloading indicate endosomal escape
and potentially additional endocytosis pathways bypassing endosomes. (E) The in vivo distribution of the siRNA–NP complexes (shown in green because of FAM
tagging of the siRNAs) is restricted to the BTIC xenograft (shown in red because of mCherry-fLuc lentiviral transduction) at day 4 after intratumoral delivery via an
s.c. osmotic pump. Distribution outside the tumor cell xenograft is very limited and is not observed in CD31+ or VE-Cadherin+ mouse brain vasculature (yellow
arrows). The border between the tumor xenograft and the FAM-tagged siRNA–NP complexes is clearly visible.
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size are key milestones of successful in vivo delivery of siRNAs, and
our solution of using a unique class of lipopolymeric nanoconstructs
to complex therapeutic siRNA duplexes accomplishes all indices in
one fell swoop (14, 15, 22, 42). Overcoming these obstacles helps
reduce off-target effects and minimizes toxicity to liver and immune
cells in vivo; however, the endothelia-targeting properties of these
NPs indicate that systemic delivery of candidate siRNAs is not ideal
for targeting brain tumors, even though tumor-induced angiogenesis
is prevalent in GBM (43) and cerebral blood flow volume is one of
the largest parts of the total cardiac output. Indeed, the bio-
distribution study of the 7C1 LPNPs used for our study indicates
negligible presence in the brain tissue (23). However, with the re-
cent recognition of perivascular niches for BTIC invasive growth
(11, 44–47), direct in vivo RNAi delivery via nano vehicles with
vasculature affinity may increase the retention and therapeutic ef-
ficacy of BTIC-targeting siRNAs in the tumor microenvironment by
minimizing off-target distribution. Based on patient data published
in the IVY Glioblastoma Atlas Project (IVY GAP; glioblastoma.
alleninstitute.org), we identified loci of high TF expression within
the bulk tumors of patients diagnosed as having various subtypes of
GBM (SI Appendix, Fig. S1). We experimented with two ap-
proaches to examine the impact of local direct delivery of the
7C1 siRNA–NP therapy (nano RNAi) to BTIC xenografts. First, we
gave two intratumoral injections of combination siRNA–LPNPs
(20 μg/kg; 5 μL per injection; 4 d apart) to mice that had been
implanted 4 d previously with 1 × 105 xenograft GBM43 cells. There
were no survival benefits compared with the control group receiving
nontargeting control siRNA–LPNP (P = 0.39, log-rank test; n = 5)
(Fig. 7A and B).We then increased the therapeutic dosing to 75 μg/kg
delivered in three separate injections 4–6 d apart starting 4 d
(96 h) after tumor cell implantation. There was a significant, but
marginal survival benefit (P = 0.045, log-rank test; n = 10; median
survival increase = 2 d) (Fig. 7C). Because repeated surgery intro-
duces stress and pain that may impact the survival of the experi-
mental animals, we opted for the convection-enhanced delivery
(CED) strategy using an Alzet osmotic pump to deliver a contin-
uous supply of the nano RNAi combination at a rate of 6 μL/24 h
for 14 d; this strategy had been successful in our previous applica-
tion in a rodent model of CNS disorders (48). MGG8 was
implanted at a dose of 1 × 105 cells per mouse; then we implanted
the pump (Durect Corp.) delivering 350 μg/kg (total average dose,
7 μg per mouse) through a brain infusion kit (Fig. 7D) 10 d after the
tumor xenograft to allow sufficient integration of the tumor cells
with the host brain microenvironment and to establish brain–blood
vessel cooperation and invasive perivascular niches. The implant
was left s.c. until the study end point. By design, there is an option to
remove the pump upon complete cargo release (by 14 d after im-
plantation) and to replace it with a new pump for continued drug
delivery for up to 36 cycles; however, we opted not to do so to
reduce surgery-related stress. This single-pump study was designed
to establish the feasibility and to document the therapeutic benefit
dynamics. The waiting period of 10 d may have enabled further
tumor cell invasion of healthy parenchyma, reducing the chance of
delivered drug coverage and leading to highly uneven therapeutic
outcomes across the five mice per group. As a result, there was a
noticeable median survival benefit of 6 d, but the result lacked
statistical significance because of variability within the small sample
size (n = 5; P = 0.35) (Fig. 7E). Next, we used MGG8 cells
implanted at the doubled dose of 2 × 105 cells per mouse to increase
the therapeutic threshold, nearly quadrupled the nano RNAi drug
dose, and reduced the waiting period after tumor implantation to
5 d. We gave the mice the 1.5 mg/kg nano combination RNAi in a
Fig. 5. Functional characterization of nano RNAi in vitro. (A) Using 7C1 LPNPs to encapsulate siRNAs against master TFs, we show that various degrees of
knockdown of TF expression can be observed across different cell lines using 100-nM combination siRNA mixtures (n = 4, *P < 0.05, ***P < 0.001, t test).
(B) Single siRNAs were used to compare the relative knockdown of TF protein levels with the combination mixture. There was synergy between TFs in the
combination (combo) strategy. Combo siRNAs provided the greatest reduction in protein level by 72 h (***P < 0.001). (C) A functional reduction in BTIC
spherogenic potential is demonstrated by a limiting dilution sphere-formation assay that shows significant differences in the ability of various cell lines to
form tumor spheres (a significant reduction in stem cell frequency in the treated cells) as a result of the combo nano RNAi therapy (n = 12, ***P < 0.001;
Pearson’s χ2 test). This effect is not seen in MES83 cells.
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14-d pump beginning 5 d after tumor implantation. A clear sta-
tistical survival benefit was seen when the combination nano
RNAi was compared with nontargeting nano siRNA controls (n =
12; P = 0.003, log-rank test) (Fig. 7F), with a median survival
extension of 8 d. Because in the nano RNAi treatment group the
first animal reached endpoint at 21 d after tumor xenograft, and
the last animal reached the end point at 34 d, i.e., 2–15 d after the
14-d nano RNAi supply in the osmotic pump was exhausted, it is
conceivable that further survival benefit can be achieved by using
either a higher drug concentration or a longer period of drug
treatment via replacement pumps. Indeed, using a larger osmotic
pump, Alzet model 2002 (delivering 200 μL at a rate of 12 μL/24 h
for 14 d) (Fig. 7G) and a GBM43 model established with 2 × 105
cells 10 d before pump implantation, we observed a benefit of 19 d
for median survival extension compared with the control group
(Fig. 7H). Although there could be a component of high-dose–
induced nonspecific toxicity (SI Appendix, Fig. S8), because the
control siRNA–LPNP treatment group showed a broadened sur-
vival curve ranging over 16–38 d, the overall tolerance of this high-
dose delivery is evident in the survival profile of the combo
siRNA-treated group (Fig. 7H).
Last, it is important to note that the intratumoral delivery of
combo siRNA–LPNP indeed inhibits the expression levels of the
core TFs based on tissue immunocytochemistry (SI Appendix, Fig.
S9) and qRT-PCR following in situ tissue collection via laser-
capture microdissection (LCM) (SI Appendix, Fig. S10); however,
once the dosing is over, i.e., when the content of the osmotic pumps
was consumed, the core TFs may revert back to high expression
levels and eventually lead to the demise of the tumor-bearing mice.
Discussion
The recognition of RNAi as a potential anticancer therapeutic
strategy coincides with a surging flux of knowledge about the ge-
netic circuits of BTICs and their regulatory impacts on epigenetic
states that underscore tumorigenesis. Genome sequencing and
transcriptional profiling of contrasting GBM subpopulations have
shed light on a large number of genetic events that divide GBM
into subclasses of tumors with contrasting hierarchical dependence
on disparate genetic aberrations, highlighting the daunting chal-
lenge for therapeutics to impede tumor growth through a unified
antitumor mechanism. Compounding the complexity of the murky
state in the cellular hierarchy within an individual GBM is the re-
cent recognition (based on single-cell RNA sequencing analysis)
that cellular heterogeneity is prevalent in individual GBMs (49).
The differentiation states of GBM cells have been implicated in the
determination of epigenetic plasticity, tumor initiation, and therapy
resistance (50, 51), highlighting the potential driving roles of BTICs
in GBM malignancy. Because numerous phenotypic markers [e.g.,
CD133 (52), SSEA-1 (53), CD44 (54), and Integrin α6 (55)] have
been used to enrich putative stemlike populations within the GBM,
Fig. 6. Functional validation of the antitumor effects of siRNA–NP complexes in vivo. To evaluate the in vivo antitumor impact of the nano RNAi strategy, mice
graftedwith GMB43-fLuc were given intratumoral combo siRNA–NP complexes against the four TFs. (A) Starting at 96 h post tumor cell xenograft implantation (p.
i.), the GBM43 fLuc signals were captured as the baseline activity (one-fold). Interspersed siRNA–NP intratumoral injections were given three times (NP1, NP2, NP3),
and the fLuc activities of GBM43 xenografts were captured at 72 h postinjection (an additional time point at 144 h after NP2 was included also). (B) Multiplexed
combo TF siRNA–NPs inhibited the fLuc activity and changed the tumor growth trajectory (blue trend line), indicating reduced tumor cell expansion in vivo.
Repeated nano RNAi therapy led to a significant reduction of fLuc activity 72 h after the second combo siRNA–NP injection (NP2; n = 10, *P < 0.05, t test), an
indicator of in vivo tumor growth arrest. Nontargeting negative control siRNAs in NPs did not stop tumor growth (red trend line). However, the antitumor effect
was not sustainable. By the third combo siRNA-NP treatment (NP3), the tumor growth trajectory was restored. However, there was no overall difference between
the two groups by ANOVA, indicating that interspersed combo siRNA-NP therapy is insufficient to stop tumor growth entirely.
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a consensus-oriented therapeutic targeting approach is unlikely to
encompass all subtypes of BTICs in a highly heterogeneous GBM.
This complexity creates a daunting task for therapeutic targeting of
malignant BTICs. Inspired by recent advances in the field of in-
duced pluripotent stem cells (56, 57), efforts have been made to
decipher the intrinsic transcriptional network of the cellular hier-
archy within the privileged BTIC subpopulations and have resulted
in the identification of four master TFs responsible for the main-
tenance of BTIC phenotypes (24). The expression of these master
TFs seems to correlate with the operation of the phenotypic
markers established previously, offering hope that similar hierar-
chical investigations could eventually shed light on common de-
nominators of tumor initiation and enable the consolidation of
therapeutic targets.
The concept that forced differentiation abolishes the malignant
epigenetic programs underlying tumorigenesis was strengthened
further, thanks to efforts in the field of leukemia (58), by the global
reset of the epigenetic states to override the tumor genome (59).
Although a single factor [e.g., bone morphogenic protein 4 (BMP4)
(60)] is capable of inducing BTIC differentiation, complex signaling
mixtures, such as serum (61), or a chromatin regulator complex, such
as PRC2 (62), demonstrate gradual and at times reversible epige-
netic override of the malignant gene circuits of BTICs. Although
small-molecule antagonists or inhibitors of the stemness signaling
pathways are being explored, the promising safety profile and gene-
targeting specificity render siRNAs the ideal therapeutic for modi-
fications of the TF-driven epigenetic state and for prodifferentiation
approaches toward malignant BTICs. Given that pro-stemness sig-
naling mechanisms continue to be identified via extensive BTIC
epigenetics analysis (63), it is clear that there are no “be-all and end-
all” BTIC targets in the context of various tumorigenic genetic
subclasses. Combination siRNA targeting of identifiable targets for
individual tumors in a personalized fashion becomes a rational goal
of therapeutic development. In our experiments, we set out to use
patient-derived tumor cells with genetically defined malignancy
drivers for siRNA targeting. Given that intratumoral heterogeneity is
likely unavoidable (49, 64, 65), subpopulations of BTICs indepen-
dent of TFs within the tumor would likely overtake the growth even
if siRNA combination therapies are effective in suppressing the
BTIC populations dependent on TFs (66, 67). This likelihood leads
to the prospect of further combined targeting of adaptive malignancy
drivers in response to TF suppression as an additional strategy to-
ward personalized precision medicine.
The key limitation to translating the latest genetic/epigenetic
discoveries to patient care is drug delivery efficiency. The brain is a
privileged organ with broad restrictions on therapeutic penetrance
across the BBB. Although promising, RNAi directed at the spe-
cialized BTIC populations intertwined within the brain vasculature
and normal brain cells face a number of challenges for distin-
guishable therapeutic benefits. First, siRNA or miRNA as RNAi
reagents must survive the RNase activities in the brain tissue mi-
croenvironment, so NP encapsulation or conjugation has become a
standard approach to shield the therapeutic targeting and in vivo
delivery of RNA from degradation. A second challenge is targeting
the tumor and administering sufficient accumulated dosing to tu-
mor cells. The third challenge is the requirement for low toxicity
and minimal off-targeting and side effects. Last, sustainable dosing
at the tumor site is necessary, given the dynamic nature of malig-
nant tumor genetic/epigenetic adaptations to therapy. Numerous
nano constructs have been designed to address each of these ele-
ments (32, 34, 35, 68, 69); our approach comprehensively combines
the favorable benefits of several modalities. It builds on the blood
vessel-targeting capacity of the customizable 7C1 lipopolymeric
nano vehicle, which has excellent safety profiles (14, 15, 23, 70). The
7C1 delivery system ensures dual strength in direct delivery to the
tumor cellular core (where the great majority of BTICs reside) and
vasculature-associated invasive niches (11, 44–47) (where residual
resistant populations of BTICs accumulate after a standard therapy
regimen). Additionally, we maintained continuous focused delivery
via a CED brain-infusion catheter that is undergoing clinical trials
for both malignant brain tumors and neurodegenerative diseases
(71–74). These combined considerations minimize the issues fre-
quently associated with nanomedicine in regards to off-target de-
livery, imbalanced biodistribution, and the potential for systemic
toxicity when high systemic dosing is required to achieve a detect-
able presence in brain tumor. Concordantly, with this approach we
still maintain the capacity to reach the invasive niches that often
develop in the intraparenchymal perivascular spaces along the brain
vasculature through local distribution and vasculature targeting.
Our current data indicate that sustained local delivery significantly
Fig. 7. In vivo assessment of the survival benefit of nano RNAi on BTIC-driven
tumorigenesis. (A) Schematic of the intratumoral bolus injection regimen.
(B) Low-dose intratumoral injection (two injections) 4 d after tumor xenograft
did not generate survival benefits (n = 5, P = 0.39, log-rank test). (C) A higher
drug dose (75 μg/kg) and more redosing (three injections) promoted survival
significant benefits for mice with the GBM43 xenograft (*P < 0.05, log-rank
test, n = 10), although the medium survival is only 2 d longer than in controls.
(D) Schematic of s.c. osmotic pump implantation. (E) A low (7-μg) nano RNAi
dose delivered via an s.c.-implanted Alzet pump did not offer significantly
longer survival, given the smaller sample size (n = 5), even though there is a
median benefit of 6 d. (F) A higher dose (1.5 mg/kg) and larger sample size
demonstrated a significant survival benefit for mice with twice as many tumor
cell xenografts (n = 12, ***P = 0.003, log-rank test). (G) Schematic of a larger
pump implantation. (H) Improved survival profile for xenograft model of
GBM43 BTICs (median survival extension = 19 d; log-rank test, *P = 0.015).
Yu et al. PNAS | Published online July 10, 2017 | E6153
M
ED
IC
A
L
SC
IE
N
CE
S
PN
A
S
PL
U
S
extends survival, whereas limited bolus intratumoral injections offer
marginal benefits, validating the logic of the delivery strategy.
Extending the CED delivery beyond the current dosing period of
14 d may offer additional survival benefit when siRNA dosing limits
per unit vehicle are in place with the current nano packaging tech-
nologies. Although there could be concerns about the potential for
nonmodified siRNA duplexes to induce innate immune response for
antitumor effects (75, 76), our use of nu/nu mouse models with hu-
man BTIC xenografts and the universal nontargeting negative siRNA
controls mitigated this common misinterpretation of antitumor re-
sults. For clinical translation, this potential impact will be assessed in
immune-competent mouse models, which could reveal the impact of
these LPNPs on the immune response of GBM.
In the current report we identify a previously unknown affinity of
7C1 LPNPs for BTICs and describe a CED strategy of 7C1 LPNP-
enabled BTIC RNAi therapy in patient-derived xenograft models of
GBM. We proved that (i) a multiplexed nanomedicine strategy for
RNAi targeting malignant BTIC genomic TF drivers is feasible;
(ii) CED-enabled intratumoral delivery offers direct evidence of
therapeutic benefits of RNAi therapy against BTICs; and (iii) limited
dosing is insufficient to overcome tumor growth despite a clear at-
tenuation of malignant tumor growth. This third finding leads to the
prospect of additional multiplexed RNAi therapies against resistant
populations of BTICs beyond the four TFs under investigation, once
the adaptive malignancy genomic drivers are identified. The study
also exposed the need to improve on the current intracranial distri-
bution of nano therapeutics beyond experimental models of CED
using Alzet s.c. osmotic pumps. In addition, nontransient RNA-based
nanomedicine therapies using new genome-editing tools, such as the
rapidly evolving CRISPR technologies, can be delivered via the
customizable LPNPs for sustained elimination of tumorigenic mo-
lecular markers (14, 70). Furthermore, continued refinement and
more customized functionalization of the NPs via surface chemistry
engineering may allow antitumor gene editing in multiple cell types
present in the tumor microenvironment (e.g., in immune cells and
astrocytes) which can be recruited in a locally coordinated anti-
malignancy campaign to boost therapeutic durability and efficiency.
Materials and Methods
Cell Culture and Reagents. A panel of patient-derived GBM cells (GBM6,
GBM12, GBM26, and GBM43, a gift from C. David James, Northwestern
University; MGG8, a gift fromM.L.S., Massachusetts General Hospital/Harvard
Medical School; andMES83, a gift from Ichiro Nakano, University of Alabama
at Birmingham and Shi-Yuan Cheng, Northwestern University) were main-
tained as neurospheres in serum-free Neurobasal or DMEM F12 medium with
B27 and N2 supplements (Thermo Fisher Scientific), broad-spectrum antibi-
otics, L-glutamine, heparin (Millipore Sigma), EGF, and basic fibroblast
growth factor (R&D Systems) (24, 25, 36).
In Vitro Single-Cell and Limiting-Dilution Spherogenic Assays. Costar polystyrene
96-well plates (Thermo Fisher Scientific) were used to plate single cells per well
(24) or in a series of 1, 3, 6, 12, 25, 50, 100, 200 cells per well in 200 μL of serum-
free medium (as described above), with 10 μL fresh medium replacements
every other day. Cells were imaged under a microscope after 7 d. A BD
FACSMelody cell sorter (BD Biosciences) was used to perform the serial dilution
plating (SI Appendix, Fig. S11) A Cytation 5 Cell Imaging Multi-Mode Reader
(BioTek) was used to collect well images. Results of the limiting dilution assay
were assessed using Extreme Limiting Dilution Analysis (ELDA) software (77).
Patient-Derived Xenograft Mouse Model of GBM.All protocols were approved by
the Institutional Animal Care and Use Committees (IACUCs) at The University of
Chicago and Northwestern University. The surgical procedures were conducted
according to NIH guidelines. Six- to eight-week-old athymic nude male or fe-
male mice were obtained from Envigo Research Models and Services and from
Charles River Laboratories and were maintained in a pathogen-free facility.
Mice were anesthetized with a ketamine HCl (25 mg/mL)/xylazine (2.5 mg/mL)
solution, and patient-derived GBM43 or MGG8 cells (without or with TF siRNA
knockdown; 1 × 105 or 2 × 105 cells in 2.5 μL sterile saline) were injected in the
mouse brain at 2.5 mm depth through a transcranial burr hole created at
coordinates 2 mm lateral and 1.5 mm caudal relative to bregma using an
established procedure (78). Standard postsurgery care was given following the
IACUC-approved protocol. No gender differences were observed in the sur-
vival period after tumor cell implantation.
Intratumoral Delivery of Combo siRNA-Encapsulating 7C1 NPs. All protocols were
approved by the IACUC at Northwestern University. Five days after tumor cell
implantation, 2–3 separate bolus intratumoral injections of siRNA-complexed 7C1
NPs were given at 4- to 6-d intervals to tumor-bearingmice through the skull burr
hole created for tumor cell implantation. Alternatively, Alzet s.c. osmotic pumps
(Durect Corporation model 1002, with a capacity of 100 μL over 14 d with a flow
rate 6 μL/24 h or model 2002, with a capacity of 200 μL over 14 d with a flow rate
12 μL/24 h) were implanted to supply continuous intratumoral delivery of the
siRNA-complexed 7C1 NPs via Brain Infusion Kit 3 (Durect Corporation), which
implants a catheter at the depth of tumor cell implantation.
BLI Assessment of Tumor Growth. Mice were given an i.p. injection of fLuc
substrate D-luciferin (GoldBio) before isoflurane anesthesia in an induction
chamber for 10 min. BLI signals of tumor growth were captured using a
PerkinElmer IVIS Spectrum System with Living Image software 96 h after the
tumor cell xenograft, 72 h after the first intratumoral NP injection (NP1),
72 h and 144 h after the second intratumoral NP injection (NP2), and 72 h
after the third intratumoral NP injection (NP3). Regions of interest (ROIs)
were drawn to cover the entire brain. The sum of the counts within the ROIs
was obtained by subtracting the background counts.
Western Blotting. The proteins were extracted using M-PER reagent (Thermo
Fisher Scientific). Equal amounts of proteins were loaded into 4–20% gradient
gels (Bio-Rad or Thermo Fisher Scientific) and transferred to an Immobilon FL
PVDF membrane (Millipore). The primary antibodies used were against human
SOX2, OLIG2 (mouse IgG, R&D Systems, and rabbit IgG, Millipore Sigma),
SALL2, POU3F2 (rabbit IgG, Bethyl Laboratories), and β-actin (Cell Signaling
Technologies). The secondary antibodies used were anti-rabbit or anti-mouse
IgGs conjugated with infrared dyes for multiplex quantitative Western Blot or
HRP-conjugated anti-rabbit or anti-mouse IgGs for chemiluminescent blotting.
Stained membranes were imaged on a Li-COR Odyssey scanner, and the data
were quantified using Image Studio Lite software (Li-COR Biosciences).
Flow Cytometry and Immunocytochemistry Analysis of TF Knockdown. To analyze
TF expression levels, tumor cells were collected after Accutase treatment and
were resuspended in Fix/Perm buffer (BioLegend) or were fixed in 2% para-
formaldehyde (PFA) followedbypermeabilizationusing0.03%TritonX-100 in PBS
at 2 × 105 cells per 200 μL per well. Cells then were stained with primary anti-
bodies against SOX2, OLIG2, SALL2, POU3F2, or isotype control IgG (eBioscience).
Allophycocyanin-labeled secondary antibodies against rabbit IgG were used to
incubate cells after washes following primary antibody incubation. Cells were
analyzed using a BD LSRFortessa analyzer and FACS Diva software (BD). The flow
cytometry data were processed using FlowJo software (FlowJo LLC). Stained cells
were fixed in 2% PFA before incubation with Vectashield mounting medium
plus DAPI (Vector Labs) for nuclei counterstains in a glass bottom 96-well plate.
Confocal microscopy was performed at the University of Chicago Integrated
Light Microscopy Facility using a 3i Marianas Yokogawa-type spinning disk
confocal microscope with an Evolve EMCCD camera (Photometrics) running Sli-
deBook v5.5 software (Intelligent Imaging Innovations). Digital images then
were processed and analyzed for quantitative measurements using Fiji Software.
CellSimple Cell Death and Proliferation Assays. A CellSimple Cell Analyzer (Cell
Signaling Technology) was used to analyze the impact of LPNP–siRNA therapy
on BTICs. A CellSimple Annexin V early apoptosis detection kit (Cell Signaling
Technology) and a Click-iT EdU Alexa-594 flow cytometry proliferation assay
kit (Thermo Fisher Scientific) were used with the CellSimple cassettes for
efficient, timely, and accurate live-cell profiling.
qRT-PCR Analysis. Total RNAwas isolated fromGBM cells using the RNeasy Plus Kit
(Qiagen). One microgram of RNA was reverse-transcribed using the iScript cDNA
conversion kit (Bio-Rad). qRT-PCR was conducted using the SYBR Green PCR Kit
(Bio-Rad) using the primers indicated in SI Appendix, Table S1. Data analysis was
performed using the 2−ΔΔCT method for relative quantification, and all sample
values were normalized to the human GAPDH expression value.
Complexing siRNA Formulations into 7C1 NPs. Purified 7C1 NPs were syn-
thesized and formulated as previously described (23). Specifically, poly-
ethyleneimine with a molecular weight of 600 (PEI600; Millipore Sigma) was
combined with 200-proof anhydrous ethanol (Koptec/VWR International)
and an epoxide-terminated C15 lipid at a lipid:PEI molar ratio equal to 14:1.
The mixture was heated at 90 °C for 48 h before purification was performed
E6154 | www.pnas.org/cgi/doi/10.1073/pnas.1701911114 Yu et al.
with a silica column as previously described (23). To formulate NPs, purified
7C1 was combined with 200-proof ethanol and 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (Avanti Polar
Lipids) at a 7C1:lipid-PEG molar ratio equal to 4:1 in a glass syringe. siRNA
was dissolved in pH 3 10 mM citrate solution (Teknova) in a separate syringe.
The two syringes were connected to a syringe pump, and the fluid was
pushed through a microfluidic device as previously described (22). The
resulting NPs were dialyzed in 1× PBS and were sterilized using a 0.22-μm
polyethersulfone syringe filter (Genesee Scientific).
NP Characterization. NP size and structure were analyzed by dynamic light
scattering (DLS) (Zetasizer NanoZS; Malvern Instruments) or cryogenic
transmission electron microscopy (cryo-TEM) as previously described. DLS
samples were measured in sterile 1× PBS at an approximate siRNA concen-
tration of 1.0–3.0 g/mL. Cryo-TEM samples were prepared in a controlled-
environment vitrification system at 25 °C and ∼100% relative humidity.
Analysis of NP Uptake Dynamics. To evaluate the uptake dynamics of the LPNP–
siRNA complexes, LPNPs were complexed with Alexa 647-conjugated siRNA
sequences and were loaded onto Accutase-dissociated single MGG8 BTICs or
control cells (bEnd3 mouse brain endothelial cells and C8D1A mouse astrocytes
from ATCC or serum-differentiated MGG8 GBM cells) for incubation for 1, 3, 12,
or 24 h. Cells without LPNP incubations were used as baseline controls. The
percentage of cells showing uptake of the Alexa 647–siRNA–NP complex was
measured using a BD LSRFortessa cell analyzer (BD Biosciences) and FlowJo
software. The intracellular locations of the endocytosed LPNPs were de-
termined via coimmunostaining with endosomal marker antibodies such as
anti-EEA1, anti-RAB5, and anti-RAB7 antibodies (Cell Signaling Technology)
using 2% PFA-fixed BTICs, and the Atto-488–conjugated secondary antibody
against rabbit IgG was used to contrast the Alexa 647-tagged siRNA–LPNP
complexes. The stained cells then were imaged under a conventional confocal
microscope at The University of Chicago Microscopy Core. Images were cap-
tured with a 3i Marianas Yokogawa-type spinning disk confocal microscope
with an Evolve EMCCD camera (Photometrics) running SlideBook v5.5 software
(Intelligent Imaging Innovations).
Super-Resolution SMLM Analysis. To enhance the optical resolution of subcellular
organelles and nanoscale LPNP aggregates further after biological uptake into
the cytosol of BTICs, we performed super-resolution imaging of BTICs after LPNP
uptakeatdifferent timepoints, usinga customSMLMsuper-resolutionnanoscopy
(79, 80). To perform SMLM imaging, 5-μL cell suspensions of each sample were
mixed with the imaging buffer and deposited at the center of a freshly cleaned
glass slide. The imaging buffer was freshly made and contained TN buffer
[50 mM Tris (pH 8.0) and 10 mMNaCl; all chemicals are fromMillipore Sigma], an
oxygen-scavenging system (0.5 mg/mL glucose oxidase), 40 μg/mL catalase and
10% (wt/vol) glucose, and 143 mM β-mercaptoethanol. A no. 1 coverslip was
used to cover the sample and was sealed with dental cement on the glass slide.
The samples were placed on the microscope stage and imaged under a total
internal reflection fluorescence objective (Nikon CFI apochromat 100×, 1.49 NA).
The 473-nm and 645-nm lasers were used to excite fluorescence from Atto-
488 and Alexa-647 fluorophores, respectively. Before acquiring SMLM images,
we used relatively low-intensity light (∼0.05W/cm2) to illuminate the sample and
recorded the conventional fluorescence image. We then increased the light in-
tensity to ∼2 kW/cm2 to switch off the dyes rapidly for SMLM imaging. We
recorded 2,000 images using an EMCCD camera (iXon Ultra 897; Andor) at a
frame rate of 50 Hz with field of view of 20 × 20 μm. The super-resolution image
was generated using a standard localization algorithm (ThunderSTORM, ImageJ
plug-in) (81). To quantify the spatial correlation of the siRNA–NP and endosome,
pair correlation functions [g(r)] were calculated using a custom MATLAB code.
Immunocytochemistry Assessment of Tumor Cell Differentiation in Vitro and
Growth in Vivo. Cultured BTIC neurospheres were treated with combo siRNA–
LPNPs in vitro for 48 h in 12-well plates containing sterile cover glasses, and
cells were fixed on the cover glasses once the morphology became indicative
of differentiation using 2% PFA. Cells then were permeabilized and in-
cubated with blocking solution, primary antibodies against differentiation
markers such as TUJ1 and NFM for neural lineage, GFAP and S100 for glial
lineage, and GalC for oligodendroglial lineage (antibody details are listed in
SI Appendix, Table S3). After they were killed, select animals were perfused
with 4% ice-cold PFA in 0.1 M PBS to collect tumor-bearing brain tissue. Fol-
lowing postfixation and cryoprotection, brain tissues were embedded in OCT
compound (Sakura-Finetek USA Inc.) and were promptly frozen on a mixture
of dry ice and isopentane (Thermo Fisher Scientific). Sectioned brain tissue
(10 or 20 μm thick) was stained for human cell markers with antibodies against
human-specific Nestin (Millipore) to identify human GBM43 and MGG8 tumor
cells. TF antibodies then were used to costain for BTIC status. Cy2-, Alexa 555-,
or Alexa 647-conjugated secondary antibodies against rabbit IgG or mouse IgG
(Thermo Fisher Scientific or Jackson ImmunoResearch) were used to visualize
specific binding. Whole-slide scans were performed using a 3DHistech Pan-
noramic Scan whole-slide scanner (Perkin-Elmer) with a Zeiss Axiocam MRm
CCD camera (Carl Zeiss Microscopy) for fluorescence or a Stingray F146C color
camera (Allied Vision Technologies) for histology.
LCM and qRT-PCR After Linear RNA Amplification. To confirm the knockdown
impact of siRNAs encapsulated in LPNPs after in vivo administration in xenograft
GBM models, freshly harvested mouse brains bearing a GBM xenograft (n = 6)
were flash-frozen with OCT compound in isopentane (Thermo Fisher Scientific)
chilled with dry ice. These brain tumors were treated with either a single 5-μL
LPNP injection (n = 3) 6 d prior or an s.c. osmotic pump via brain infusion kit for
14 d (n = 3). An RNase-free work environment was ensured by wiping the
working surfaces of benchtops and the machinery inside the Leica cryostat
(model CM1860 UV, Leica Biosystems Nusslock GmbH) with 100% ethanol. The
frozen block was then cut into 10-μm-thick sections, collected onMembraneSlide
1.0 PEN (Carl Zeiss Microscopy GmbH), and kept in a freezer at −80 °C until LCM
application. A Zeiss Palm LCM system at the Northwestern University Center for
Advanced Microscopy Core Facility was used to dissect the brain tumor tissue
that was infused with the LPNP–siRNA complexes. The siRNA encapsulated in
LPNPs had a FAM (fluorescein) tag; thus the presence of green fluorescence in
the tissue was used as a mark for dissection element selection (SI Appendix, Fig.
S10). AdhesiveCap 200 PCR tubes (Carl Zeiss Microscopy GmbH) were used to
collect dissected tissue from the tissue infused with LPNP–siRNA and from control
tissues in the normal parts of the mouse brain (different slides were used for
different LCM samples to avoid identity confusion). Samples were kept on dry ice.
A MessageBOOSTER cDNA Synthesis kit (catalog no. MBCL90310; Lucigen Corp.)
was used for linear amplification of the RNA samples for cDNA conversion, and an
RNA Clean & Concentrator kit (catalog no. R1015; Zymo Research) was used to
purify RNA before cDNA synthesis for qRT-PCR analysis of TF expression levels.
Statistical Analysis. All statistical analyses were performed as Student’s t test
using GraphPad Prism 5 (GraphPad Software Inc.) unless otherwise specified.
The sample size for each group was ≥3, where n represents biological rep-
licates. All numerical data are reported as mean ± SEM. A Kaplan–Meier
survival curve was generated, and a log-rank test was applied to compare
survival distributions. For all survival experiments n represents number of
animals per group. All reported P values were two-sided and were consid-
ered to be statistically significant at *P < 0.05, **P < 0.01, ***P < 0.001.
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